JP2022516574A5 - - Google Patents
Info
- Publication number
- JP2022516574A5 JP2022516574A5 JP2021539599A JP2021539599A JP2022516574A5 JP 2022516574 A5 JP2022516574 A5 JP 2022516574A5 JP 2021539599 A JP2021539599 A JP 2021539599A JP 2021539599 A JP2021539599 A JP 2021539599A JP 2022516574 A5 JP2022516574 A5 JP 2022516574A5
- Authority
- JP
- Japan
- Prior art keywords
- amyloid
- pharmaceutical composition
- disease
- peptide
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024207280A JP2025041635A (ja) | 2019-01-07 | 2024-11-28 | 新規ペプチドとその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962789114P | 2019-01-07 | 2019-01-07 | |
| US62/789,114 | 2019-01-07 | ||
| PCT/US2020/012323 WO2020146236A1 (en) | 2019-01-07 | 2020-01-06 | Novel peptides and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024207280A Division JP2025041635A (ja) | 2019-01-07 | 2024-11-28 | 新規ペプチドとその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022516574A JP2022516574A (ja) | 2022-02-28 |
| JP2022516574A5 true JP2022516574A5 (cg-RX-API-DMAC7.html) | 2023-01-23 |
Family
ID=71520880
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539599A Pending JP2022516574A (ja) | 2019-01-07 | 2020-01-06 | 新規ペプチドとその使用 |
| JP2024207280A Pending JP2025041635A (ja) | 2019-01-07 | 2024-11-28 | 新規ペプチドとその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024207280A Pending JP2025041635A (ja) | 2019-01-07 | 2024-11-28 | 新規ペプチドとその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220064214A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3908307A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022516574A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220004618A (cg-RX-API-DMAC7.html) |
| CN (2) | CN113853382A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2020207203A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3125552A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL284666A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020146236A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4966848A (en) * | 1988-02-08 | 1990-10-30 | The General Hospital Corporation | Isolation, purification, characterization, cloning and sequencing of N α-acetyltransferase |
| US5223421A (en) * | 1989-10-25 | 1993-06-29 | The General Hospital Corporation | Identification of methionine Nα-acetyltransferase |
| US5688489A (en) * | 1995-09-15 | 1997-11-18 | Resolution Pharmaceuticals, Inc. | Non-receptor mediated imaging agents |
| US6777388B1 (en) * | 1998-08-21 | 2004-08-17 | Clf Medical Technology Acceleration Program, Inc. | Leptin-related peptides |
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US20030077740A1 (en) * | 2001-03-05 | 2003-04-24 | Schubert David R. | Presenilin/Crk binding polypeptides (PCBP) and methods of use thereof |
| US8129334B2 (en) * | 2006-03-31 | 2012-03-06 | The Regents Of The University Of California | Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory |
| JP2013526518A (ja) * | 2010-05-13 | 2013-06-24 | ザ ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション | Ｍｃｉおよびアルツハイマー病の処置 |
| CN106456799B (zh) * | 2014-06-03 | 2020-05-22 | 江苏佳瑞生物技术有限公司 | 肽-药物偶联物 |
-
2020
- 2020-01-06 AU AU2020207203A patent/AU2020207203A1/en not_active Abandoned
- 2020-01-06 US US17/420,927 patent/US20220064214A1/en active Pending
- 2020-01-06 CN CN202080017996.0A patent/CN113853382A/zh active Pending
- 2020-01-06 WO PCT/US2020/012323 patent/WO2020146236A1/en not_active Ceased
- 2020-01-06 EP EP20738687.1A patent/EP3908307A4/en active Pending
- 2020-01-06 KR KR1020217024603A patent/KR20220004618A/ko active Pending
- 2020-01-06 CN CN202210033802.7A patent/CN114437173A/zh active Pending
- 2020-01-06 CA CA3125552A patent/CA3125552A1/en active Pending
- 2020-01-06 JP JP2021539599A patent/JP2022516574A/ja active Pending
-
2021
- 2021-07-06 IL IL284666A patent/IL284666A/en unknown
-
2024
- 2024-11-28 JP JP2024207280A patent/JP2025041635A/ja active Pending
-
2026
- 2026-01-14 AU AU2026200229A patent/AU2026200229A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Khanna et al. | Therapeutic strategies for the treatment of tauopathies: Hopes and challenges | |
| Bayer | Proteinopathies, a core concept for understanding and ultimately treating degenerative disorders? | |
| Takeda et al. | Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders | |
| Jokar et al. | Recent advances in the design and applications of amyloid-β peptide aggregation inhibitors for Alzheimer’s disease therapy | |
| Tropea et al. | Nitric oxide/cGMP/CREB pathway and amyloid-beta crosstalk: from physiology to Alzheimer's disease | |
| Wu et al. | Crosstalk between macroautophagy and chaperone-mediated autophagy: implications for the treatment of neurological diseases | |
| Bittar et al. | Prospects for strain-specific immunotherapy in Alzheimer’s disease and tauopathies | |
| JP6029280B2 (ja) | Ｄ−ペプチドを有する抗−アミロイドβ−ペプチド抗体を製造するための組成物 | |
| Zhou et al. | Alzheimer's disease and prion protein | |
| JP2014502141A5 (cg-RX-API-DMAC7.html) | ||
| JP2012520852A5 (cg-RX-API-DMAC7.html) | ||
| EA201890313A1 (ru) | Гуманизированные антитела к пироглутаматному варианту бета-амилоида | |
| Rösener et al. | A d-enantiomeric peptide interferes with heteroassociation of amyloid-β oligomers and prion protein | |
| JP2017532068A5 (cg-RX-API-DMAC7.html) | ||
| Kraskovskaya et al. | Tripeptides restore the number of neuronal spines under conditions of in vitro modeled Alzheimer’s disease | |
| JP2022513331A5 (cg-RX-API-DMAC7.html) | ||
| JP7428404B2 (ja) | Ｇｓｘ１を使用した脊髄損傷（ｓｃｉ）および脳損傷の処置 | |
| JP2009519025A5 (cg-RX-API-DMAC7.html) | ||
| JP2022516574A5 (cg-RX-API-DMAC7.html) | ||
| DE102010017130A1 (de) | Hybrid-Verbindung, deren Verwendung und Verfahren zu deren Herstellung | |
| WO2020123977A3 (en) | Glial fibrillary acidic protein targeting immuno-and aptamer-based-therapy for neuroinjury, neurodegeneration, neuro-disease, and neuro-repair | |
| US20180170983A1 (en) | New Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Mild Cognitive Impairment | |
| JP2025041635A5 (cg-RX-API-DMAC7.html) | ||
| EP1392347B1 (en) | Preventing cell death using segments of neural thread proteins | |
| JP2018050605A (ja) | 筋萎縮性側索硬化症、及び前頭側頭型認知症の病態誘導人工合成遺伝子、及びこれを用いた病態モデル |